Dynorphin-independent spinal cannabinoid antinociception

L. R. Gardell, M. H. Ossipov, Todd W Vanderah, J. Lai, Frank Porreca

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Spinal antinociception produced by delta 9-tetrahydro-cannabinol (Δ9-THC) and other cannabinoid agonists has been suggested to be mediated by the release of dynorphin acting at the kappa opioid receptor. Alternatively, as cannabinoid receptors are distributed appropriately in the pain transmission pathway, cannabinoid agonists might act directly at the spinal level to inhibit nociception, without requiring dynorphin release. Here, these possibilities were explored using mice with a deletion of the gene encoding prodynorphin. Antinociceptive dose-response curves were constructed for spinal Δ9-THC and WIN 55,212-2 in prodynorphin knock-out mice and in wild-type littermates. WIN 55,212-2 and Δ9-THC were equipotent in the wild-type and prodynorphin knock-out mice. Spinal pretreatment with a kappa opioid receptor antagonist, nor-binaltorphimine (nor-BNI), did not alter the dose-response curves for either WIN 55,212-2 or Δ9-THC in prodynorphin knock-out and wild-type mice. However, the same dose of nor-BNI used blocked U50,488H-induced antinociception in both wild-type and prodynorphin knock-out mice, confirming kappa opioid receptor activity. Pretreatment with SR141716A, a cannabinoid receptor antagonist blocked the antinociceptive actions of both WIN 55,212-2 and Δ9-THC. These data support the conclusion that antinociception produced by spinal cannabinoids are likely to be mediated directly through activation of cannabinoid receptors without the requirement for dynorphin release or activation of kappa opioid receptors.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalPain
Volume100
Issue number3
DOIs
StatePublished - Dec 2002

Fingerprint

Cannabinol
Dynorphins
Cannabinoids
kappa Opioid Receptor
Knockout Mice
Cannabinoid Receptor Agonists
Cannabinoid Receptors
rimonabant
Cannabinoid Receptor Antagonists
Nociception
Narcotic Antagonists
Gene Deletion
preproenkephalin
Pain
Win 55212-2

Keywords

  • Cannabinoid agonists
  • Dynorphin
  • Spinal antinociception

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Neuroscience(all)
  • Pharmacology
  • Clinical Psychology

Cite this

Dynorphin-independent spinal cannabinoid antinociception. / Gardell, L. R.; Ossipov, M. H.; Vanderah, Todd W; Lai, J.; Porreca, Frank.

In: Pain, Vol. 100, No. 3, 12.2002, p. 243-248.

Research output: Contribution to journalArticle

Gardell, L. R. ; Ossipov, M. H. ; Vanderah, Todd W ; Lai, J. ; Porreca, Frank. / Dynorphin-independent spinal cannabinoid antinociception. In: Pain. 2002 ; Vol. 100, No. 3. pp. 243-248.
@article{99bb233e526a46478ff23c12746ed910,
title = "Dynorphin-independent spinal cannabinoid antinociception",
abstract = "Spinal antinociception produced by delta 9-tetrahydro-cannabinol (Δ9-THC) and other cannabinoid agonists has been suggested to be mediated by the release of dynorphin acting at the kappa opioid receptor. Alternatively, as cannabinoid receptors are distributed appropriately in the pain transmission pathway, cannabinoid agonists might act directly at the spinal level to inhibit nociception, without requiring dynorphin release. Here, these possibilities were explored using mice with a deletion of the gene encoding prodynorphin. Antinociceptive dose-response curves were constructed for spinal Δ9-THC and WIN 55,212-2 in prodynorphin knock-out mice and in wild-type littermates. WIN 55,212-2 and Δ9-THC were equipotent in the wild-type and prodynorphin knock-out mice. Spinal pretreatment with a kappa opioid receptor antagonist, nor-binaltorphimine (nor-BNI), did not alter the dose-response curves for either WIN 55,212-2 or Δ9-THC in prodynorphin knock-out and wild-type mice. However, the same dose of nor-BNI used blocked U50,488H-induced antinociception in both wild-type and prodynorphin knock-out mice, confirming kappa opioid receptor activity. Pretreatment with SR141716A, a cannabinoid receptor antagonist blocked the antinociceptive actions of both WIN 55,212-2 and Δ9-THC. These data support the conclusion that antinociception produced by spinal cannabinoids are likely to be mediated directly through activation of cannabinoid receptors without the requirement for dynorphin release or activation of kappa opioid receptors.",
keywords = "Cannabinoid agonists, Dynorphin, Spinal antinociception",
author = "Gardell, {L. R.} and Ossipov, {M. H.} and Vanderah, {Todd W} and J. Lai and Frank Porreca",
year = "2002",
month = "12",
doi = "10.1016/S0304-3959(02)00173-2",
language = "English (US)",
volume = "100",
pages = "243--248",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Dynorphin-independent spinal cannabinoid antinociception

AU - Gardell, L. R.

AU - Ossipov, M. H.

AU - Vanderah, Todd W

AU - Lai, J.

AU - Porreca, Frank

PY - 2002/12

Y1 - 2002/12

N2 - Spinal antinociception produced by delta 9-tetrahydro-cannabinol (Δ9-THC) and other cannabinoid agonists has been suggested to be mediated by the release of dynorphin acting at the kappa opioid receptor. Alternatively, as cannabinoid receptors are distributed appropriately in the pain transmission pathway, cannabinoid agonists might act directly at the spinal level to inhibit nociception, without requiring dynorphin release. Here, these possibilities were explored using mice with a deletion of the gene encoding prodynorphin. Antinociceptive dose-response curves were constructed for spinal Δ9-THC and WIN 55,212-2 in prodynorphin knock-out mice and in wild-type littermates. WIN 55,212-2 and Δ9-THC were equipotent in the wild-type and prodynorphin knock-out mice. Spinal pretreatment with a kappa opioid receptor antagonist, nor-binaltorphimine (nor-BNI), did not alter the dose-response curves for either WIN 55,212-2 or Δ9-THC in prodynorphin knock-out and wild-type mice. However, the same dose of nor-BNI used blocked U50,488H-induced antinociception in both wild-type and prodynorphin knock-out mice, confirming kappa opioid receptor activity. Pretreatment with SR141716A, a cannabinoid receptor antagonist blocked the antinociceptive actions of both WIN 55,212-2 and Δ9-THC. These data support the conclusion that antinociception produced by spinal cannabinoids are likely to be mediated directly through activation of cannabinoid receptors without the requirement for dynorphin release or activation of kappa opioid receptors.

AB - Spinal antinociception produced by delta 9-tetrahydro-cannabinol (Δ9-THC) and other cannabinoid agonists has been suggested to be mediated by the release of dynorphin acting at the kappa opioid receptor. Alternatively, as cannabinoid receptors are distributed appropriately in the pain transmission pathway, cannabinoid agonists might act directly at the spinal level to inhibit nociception, without requiring dynorphin release. Here, these possibilities were explored using mice with a deletion of the gene encoding prodynorphin. Antinociceptive dose-response curves were constructed for spinal Δ9-THC and WIN 55,212-2 in prodynorphin knock-out mice and in wild-type littermates. WIN 55,212-2 and Δ9-THC were equipotent in the wild-type and prodynorphin knock-out mice. Spinal pretreatment with a kappa opioid receptor antagonist, nor-binaltorphimine (nor-BNI), did not alter the dose-response curves for either WIN 55,212-2 or Δ9-THC in prodynorphin knock-out and wild-type mice. However, the same dose of nor-BNI used blocked U50,488H-induced antinociception in both wild-type and prodynorphin knock-out mice, confirming kappa opioid receptor activity. Pretreatment with SR141716A, a cannabinoid receptor antagonist blocked the antinociceptive actions of both WIN 55,212-2 and Δ9-THC. These data support the conclusion that antinociception produced by spinal cannabinoids are likely to be mediated directly through activation of cannabinoid receptors without the requirement for dynorphin release or activation of kappa opioid receptors.

KW - Cannabinoid agonists

KW - Dynorphin

KW - Spinal antinociception

UR - http://www.scopus.com/inward/record.url?scp=0036897758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036897758&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(02)00173-2

DO - 10.1016/S0304-3959(02)00173-2

M3 - Article

C2 - 12467995

AN - SCOPUS:0036897758

VL - 100

SP - 243

EP - 248

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -